粪便隐血及肿瘤标志物联合检验在诊断结直肠癌中的临床价值分析

摘要

目的 探索粪便隐血及肿瘤标志物联合检验在诊断结直肠癌中的临床价值.方法 在2017年6月-2018年6月期间方便选取对照组110名健康体检者、观察组110例疑似结直肠癌患者为实验对象, 且均进行肿瘤标志物(TPA、CA242、CA724、CA199、CEA水平) 和粪便隐血等指标的检测.结果 观察组TPA (185.45±8.95)U/L、CA242(15.86±2.63)U/mL、CA724(26.47±2.43)U/mL、CA199(45.39±3.22)U/mL、CEA水平(15.86±1.35)μg/L均高于对照组(t=83.532 3,t=25.257 4,t=52.242 9,t=41.371 3,t=41.988 9,P＜0.05),同时粪便隐血+肿瘤标志物诊断特异性(92.86％)、敏感性(97.92％)均高于单方面诊断方式,误诊率(7.14％)、漏诊率(2.08％)低于单方面诊断方式(P＜0.05).结论 对结直肠癌患者实施粪便隐血+肿瘤标志物联合诊断价值明显.%Objective To explore the clinical value of combined detection of fecal occult blood and tumor markers in the diagnosis of colorectal cancer. Methods From June 2017 to June 2018, 110 healthy subjects in the control group and 110 suspected colorectal cancer patients in the observation group were convenient selected as experimental subjects, and tumor markers (TPA, CA242, CA724, CA199, and CEA levels) and fecal occult blood. Results TPA (185.45±8.95) U/L, CA242 (15.86±2.63) U/mL, CA724 (26.47±2.43)U/mL, CA199 (45.39±3.22)U/mL, CEA level (15.86±1.35) ug/L was higher than the control group (t=83.532 3, t=25.257 4, t=52.242 9,t=41.371 3, t=41.988 9, P＜0.05), and fecal occult blood+tumor marker diagnostic specificity (92.86％), sensitivity (97.92％) was higher than that of unilateral diagnosis. The rate of misdiagnosis (7.14％) and missed diagnosis (2.08％) was lower than that of unilateral diagnosis (P＜0.05). Conclusion The combined diagnosis of fecal occult blood + tumor markers in patients with colorectal cancer is significant.